Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its Q2 2021 financial results, revealing a net loss of $22.1 million, up from $0.2 million a year prior, primarily due to reduced revenue and increased expenses. Total revenue fell to $2.2 million from $13.4 million in Q2 2020. Cash and equivalents rose to $260.5 million, expected to fund operations into 2023. The company anticipates topline data from the Phase 2b XEN1101 X-TOLE trial by mid-October, a potential inflection point. Clinical trials for XEN496 and XEN007 are ongoing, with other partnered milestones expected in 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 12th Annual Wedbush PacGrow Healthcare Conference. The company will engage in one-on-one investor meetings and a virtual panel discussion titled “Got My Mind Set On You - Advancing Novel Epilepsy Targets.”
The panel is scheduled for August 11, 2021, from 11:30 am to 12 pm Eastern Time, featuring Dr. Simon Pimstone, Executive Chair of the Board. Interested parties can find further details and a link to the live webcast on the Investors section of Xenon's website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will announce its Q2 2021 financial results after the U.S. markets close on August 11, 2021. Management will hold a conference call and live audio webcast at 4:30 pm ET to discuss these results and provide corporate updates. Investors can access the webcast via the Xenon website. The details are subject to change, and webcasts will be available for replay after the event.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its upcoming participation in the virtual William Blair Biotech Focus Conference 2021. This event is scheduled for Thursday, July 15, 2021, from 10 am to 10:45 am Eastern Time. Key participants include Ian Mortimer, President and CEO, and Dr. Simon Pimstone, Executive Chair of the Board. For further details and a link to the live webcast, visit Xenon’s official website. Webcasts will be available for replay post-event for 30 days. Xenon is focused on developing innovative therapies for neurological disorders.
Xenon Pharmaceuticals (NASDAQ: XENE) announced the completion of patient randomization for its XEN1101 Phase 2b 'X-TOLE' clinical trial, exceeding the original target of 300 to 326 patients. Topline results are expected between late September and mid-October 2021. The trial aims to assess the efficacy of XEN1101 for treating focal epilepsy, with the primary endpoint focusing on changes in monthly seizure frequency. A live webinar will feature leading experts discussing the trial and broader epilepsy landscape, occurring on July 12, 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) held its Annual Meeting on June 3, 2021, announcing a leadership transition with Ian Mortimer as the new CEO and Sherry Aulin as CFO. Dr. Simon Pimstone transitions to Executive Chair, recognizing the contributions of long-serving board members. Elizabeth Garofalo was elected to the board, bringing extensive experience in neurology. The company focuses on developing therapies for neurological disorders, emphasizing its pipeline targeting unmet medical needs in epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the Jefferies 2021 Virtual Healthcare Conference on June 2, 2021, at 3:00 PM ET. The event will feature a fireside chat accessible via a live webcast. This participation highlights Xenon's commitment to advancing its pipeline of innovative therapeutics for neurological disorders, particularly focusing on epilepsy. Interested investors can find more information on the company's presentations and webcasts on their investor website. Note that the schedule is subject to change.
Xenon Pharmaceuticals reported Q1 2021 financial results, highlighting a net loss of $15.8 million, compared to $7.5 million in Q1 2020. Total revenue for the quarter was $4.4 million, down from $7.1 million year-over-year. The company completed patient screening in the Phase 2b ‘X-TOLE’ clinical trial for XEN1101 and anticipates topline data by Q3 2021. Following a public offering, Xenon bolstered its cash reserves to $274.7 million, sufficient to fund operations into 2023. The company also aims to advance multiple clinical trials targeting neurological disorders, including major depressive disorder.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will disclose its first quarter 2021 financial results on May 11, 2021, after U.S. market close. A live conference call is scheduled for 4:30 PM ET, accessible via phone or through Xenon’s investor website. The company focuses on developing innovative neurology therapies, particularly for epilepsy, with a portfolio aimed at addressing significant medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in two upcoming virtual investor conferences. The first is the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 am ET, accessible via a live webcast. The second is the 2021 Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 3:00 pm ET, also available through a live webcast. The company focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found on their investor website.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
